Paal Brunsvig

Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Bjørn Henning Grønberg, Roy M. Bremnes, Øystein Fløtten et al. · Journal of Clinical Oncology · 2009 · 289 citations · Full text

Cancer Quality, Gemcitabine Plus Carboplatin, Cancer Management +17

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

Paal Brunsvig, Steinar Aamdal, Gunnar Kvalheim et al. · Cancer Immunology Immunotherapy · 2006 · 243 citations · Full text

Telomerase Peptide Vaccination, Cancer Immunosurveillance, Phase I/ii Study +11

Hypofractionated Palliative Radiotherapy (17 Gy per two fractions) in Advanced Non–Small-Cell Lung Carcinoma Is Comparable to Standard Fractionation for Symptom Control and Survival: A National Phase III Trial

Stein Sundstrøm, Roy M. Bremnes, Ulf Aasebø et al. · Journal of Clinical Oncology · 2004 · 175 citations · Full text

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial

Paal Brunsvig, Jon Amund Kyte, Christian Kersten et al. · Clinical Cancer Research · 2011 · 155 citations

Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer

Wolfgang Lilleby, Gustav Gaudernack, Paal Brunsvig et al. · Cancer Immunology Immunotherapy · 2017 · 95 citations · Full text

Vaccination, Urology, Genitourinary Cancer +9